本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Cyclacel Pharmaceuticals

6.37
0.0000
成交量:- -
成交額:145.77萬
市值:1,425.11萬
市盈率:-0.66
高:6.37
開:6.37
低:6.37
收:6.37
52周最高:597.60
52周最低:3.08
股本:223.90萬
流通股本:96.66萬
量比:- -
換手率:- -
股息:0.00
股息率:0.02%
每股收益(TTM):-9.6620
每股收益(LYR):-502.4648
淨資產收益率:-276.80%
總資產收益率:-102.83%
市淨率:3.93
市盈率(LYR):-0.01

資料載入中...

2025/09/12

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2025/09/12

重要事件披露

Form 8-K - Current report
2025/09/05

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2025/09/05

重要事件披露

Form 8-K - Current report
2025/09/04

重要事件披露

Form 8-K - Current report
2025/09/02

重要事件披露

Form 8-K - Current report
2025/08/28

重要事件披露

Form 8-K - Current report
2025/08/25

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2025/08/14

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/08/13

重要事件披露

Form 8-K - Current report
2025/08/13

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2025/08/13

重要事件披露

Form 8-K - Current report
2025/07/31

[修訂]招股説明書

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2025/07/28

重要事件披露

Form 8-K - Current report
2025/07/24

SEC問詢函

Form CORRESP - Correspondence
2025/07/24

招股説明書

Form S-1 - General form for registration of securities under the Securities Act of 1933
2025/07/24

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/07/16

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2025/07/16

重要事件披露

Form 8-K - Current report
2025/07/07

企業合併公告

Form 425 - Prospectuses and communications, business combinations